Jacques Galipeau

 

Jacques Galipeau, M.D. FRCP(C) is the Don and Marilyn Anderson Professor of Oncology within the Department of Medicine and UW Carbone Comprehensive Cancer Center at the University of Wisconsin in Madison, and is the inaugural Assistant Dean for Therapeutics Discovery and Development at the University of Wisconsin School of Medicine & Public Health.

Dr. Galipeau obtained his Medical Degree from the University of Montreal and completed specialty training in internal medicine at McGill University. He went on to the Tufts-affiliated New England Medical Center in Boston for three years of subspecialty training in Hematology & Medical Oncology followed by a two-year scientific fellowship in gene therapy at St. Jude Children’s Research Hospital in Memphis, Tennessee. Starting in 1997, Dr. Galipeau served as faculty at McGill University before joining Emory University in 2009 as a Professor of Hematology and Oncology and Director of the Emory Personalized Immunotherapy Center. Dr. Galipeau is a board-certified Hematologist with an active clinical practice in consultative benign hematology.

Jacques Galipeau has initiated and developed an NIH-funded research program in the study and use of mesenchymal stromal cells as an immunotherapy of catastrophic illnesses including cancer and immune disease. He is an internationally recognized expert in translational development of cell therapies and the sponsor of a series of FDA-sanctioned clinical trials examining the use of autologous marrow-derived mesenchymal stromal cells for immune disorders, including Crohn’s disease and graft vs host disease. Dr. Galipeau has also developed the field of fusion-engineered cytokines known as fusokines, as a novel pharmaceutical means of treating immune disorders and cancer.

Dr. Galipeau is the director of the University of Wisconsin Program for Advanced Cell Therapy whose mission is to develop personalized cell therapies for immune and malignant disorders and to promote and deploy first-in-human clinical trials of UW cell therapy innovations to improve outcomes for children and adults.

Aligned Research Focus:

Mesenchymal stromal cells basic science and translational use, cell culture, B-regulatory cells, NK cells, activated lymphoid cells

Organ System/Disease Focus:

Crohn’s disease, GVHD, Multiple Sclerosis and neurodegenerative disease, cancer immunotherapy, tissue injury

 

Curriculum Vitae

Department of Medicine Staff Page

View Publications on PubMed